The US rare neurological disease treatment market is advancing as pharmaceutical and biotechnology companies increase efforts to develop targeted therapies for complex neurological and neuromuscular disorders. Growing investment in gene therapies, RNA-based treatments, biologics, and other precision approaches is expanding therapeutic options for patients with limited treatment choices. Strong...